COMPASS Pathways plc CMPS 深 滬
等待開盤 11-26 09:30:00 美东时间
5.20
+0.020
+0.39%
華盛通- 最 高5.28
- 今 開5.16
- 成交量 97.15万股
- 最 低 5.08
- 昨 收 5.18
- 總市值 4.99亿
- 52周最高 7.085
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.25
- 委 比 -85.06%
- 總股本 9601.70万
- 歷史最高 61.69
- 量 比 0.71
- 振 幅 3.86%
- 歷史最低 2.25
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $11
Morgan Stanley analyst Vikram Purohit maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $10 to $11.
11-06 02:04
CORRECTION: Compass Pathways Q3 Adj. EPS $(0.38) Beats $(0.39) Estimate
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 32.14 percent increase over losses of $(0.56) per share from
11-04 22:38
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Evoke Pharma (NASDAQ:EVOK) shares moved upwards by 134.4% to $10.76 dur...
11-04 20:06
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
NeuroKaire Enters R&D Collaboration With COMPASS Pathways To Advance Precision Psychiatry And Neurology
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health NeuroKaire, a pioneer in precision psychiatry and neurology,
10-30 20:38
Compass Pathways Appoints Dr. Jeffrey Jonas to Board
COMPASS Pathways ( ($CMPS) ) has shared an update. On October 26, 2025, Compass...
10-29 18:57
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-suggests/
10-14 01:28
BTIG Maintains Buy on Compass Pathways, Raises Price Target to $14
BTIG analyst Thomas Shrader maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $7 to $14.
10-14 01:17
